Abstract: Excessive activation of Burton’s tyrosine kinase (BTK) resulted in transduction of downstream signaling pathways, which led to transformation and proliferation of B cell tumors to resist apoptosis and promote cell survival. Therefore, many researchers devoted to explore key BTK inhibitors against tumor cell proliferation-related cellular signal transduction pathway. Ibrutinib has been identified as a candidated drug with efficiency on specific target –BTK. So far, ibrutinib as a Bruton's tyrosine kinase inhibitor has become an important drug against B-cell tumor drugs and the patients with B-cell tumors showed quite good response to ibrutinib in the preliminary clinical trials.

Key words: Bruton’s Tyrosine Kinase , Ibrutinib, B-cell malignancy